论文部分内容阅读
目的观察国产比索洛尔对高血压合并2型糖尿病患者糖代谢及血压的影响情况。方法将符合纳入标准的高血压合并2型糖尿病患者随机分组。观察治疗前后患者糖化血红蛋白(HbA1c)、空腹血糖、糖耐量和血压等的变化。结果共有92例患者完成研究,其中比索洛尔组47例,卡托普利组45例。治疗前和经12周治疗后两组HbA1c、空腹血糖、餐后2h血糖、收缩压和舒张压差异均无统计学意义(P=0.05)。结论本研究表明比索洛尔作为高选择性β1受体阻滞剂,对于原发性高血压合并2型糖尿病患者糖代谢无明显不良影响,同时具有良好的降压效果。
Objective To observe the effects of domestic bisoprolol on glucose metabolism and blood pressure in patients with type 2 diabetes mellitus complicated with hypertension. Methods Eligible patients with type 2 diabetes and hypertension were randomly assigned. The changes of HbA1c, fasting blood glucose, glucose tolerance and blood pressure in patients before and after treatment were observed. Results A total of 92 patients completed the study, including 47 cases in the bisoprolol group and 45 in the captopril group. HbA1c, fasting blood glucose, 2h postprandial blood glucose, systolic and diastolic blood pressures were not significantly different between before treatment and after 12 weeks of treatment (P = 0.05). Conclusion This study shows that bisoprolol as a highly selective β1 blocker has no adverse effect on glycometabolism in patients with essential hypertension complicated with type 2 diabetes mellitus, and has a good antihypertensive effect.